Biocytogen forecasts sharp 2025 profit surge on overseas growth and industry rebound

An announcement from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) is now available.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported strong preliminary results for 2025, with total operating revenue rising 40.63% year on year to RMB1.38 billion and net profit attributable to shareholders surging more than fourfold to RMB173.2 million. The company’s total assets expanded 54.20% to RMB3.72 billion, while equity attributable to owners jumped 160.76%, lifting basic earnings per share to RMB0.43 and return on net assets to 16.85%.

Management attributed the performance to continued expansion in overseas markets and a recovery in China’s biopharmaceutical industry, which together fueled rapid revenue growth. An innovation-driven strategy with sustained R&D spending and lean management initiatives helped preserve high gross margins and improve operating efficiency, significantly enhancing the group’s profitability and strengthening its financial position for future growth.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biopharmaceutical company focused on innovative drug discovery and development. The group targets both domestic and overseas markets, leveraging high-intensity research and development investment to build core technological barriers and maintain high gross profit levels in a recovering biopharmaceutical sector.

Average Trading Volume: 1,887,777

Technical Sentiment Signal: Buy

Current Market Cap: HK$20.35B

Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.